{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T10:08:12Z","timestamp":1746785292130},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00347-018-0785-y","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T12:33:54Z","timestamp":1537878834000},"page":"189-200","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Behandlung der Chorioretinopathia centralis serosa mittels Aldosteronantagonisten"],"prefix":"10.1007","volume":"116","author":[{"given":"B.","family":"Cakir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"key":"785_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00347-013-3001-0","volume":"111","author":"M Maier","year":"2014","unstructured":"Maier M, Stumpfe S, Feucht N, Strobl P, Rath V, Lohmann CP (2014) Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy. Ophthalmologe 111:173\u2013180","journal-title":"Ophthalmologe"},{"key":"785_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.05.003","author":"A Daruich","year":"2015","unstructured":"Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. \n                    https:\/\/doi.org\/10.1016\/j.preteyeres.2015.05.003","journal-title":"Prog Retin Eye Res"},{"key":"785_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","volume":"115","author":"AS Kitzmann","year":"2008","unstructured":"Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980\u20132002. Ophthalmology 115:169\u2013173","journal-title":"Ophthalmology"},{"key":"785_CR4","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0161-6420(96)30386-2","volume":"103","author":"RF Spaide","year":"1996","unstructured":"Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996) Central serous chorioretinopathy in younger and older adults. Ophthalmology 103:2070\u20132079 (discussion 2079\u20132080)","journal-title":"Ophthalmology"},{"key":"785_CR5","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ophtha.2014.09.026","volume":"122","author":"EK Jong de","year":"2015","unstructured":"de Jong EK, Breukink MB, Schellevis RL, Bakker B, Mohr JK, Fauser S, Keunen JEE, Hoyng CB, den Hollander AI, Boon CJF (2015) Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 122:562\u2013570","journal-title":"Ophthalmology"},{"key":"785_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/IAE.0000000000000837","volume":"36","author":"B Liu","year":"2016","unstructured":"Liu B, Deng T, Zhang J (2016) Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina 36:9\u201319","journal-title":"Retina"},{"key":"785_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","volume":"86","author":"M Wang","year":"2008","unstructured":"Wang M, Munch IC, Hasler PW, Pr\u00fcnte C, Larsen M (2008) Central serous chorioretinopathy. Acta Ophthalmol (Copenh) 86:126\u2013145","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"785_CR8","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1097\/IAE.0000000000001443","volume":"37","author":"A Daruich","year":"2017","unstructured":"Daruich A, Matet A, Marchionno L, De Azevedo J\u2011D, Ambresin A, Mantel I, Behar-Cohen F (2017) Acute central serous chorioretinopathy: factors influencing episode duration. Retina 37:1905\u20131915","journal-title":"Retina"},{"issue":"111","key":"785_CR9","first-page":"1229","volume":"1993","author":"EA Bouzas","year":"1960","unstructured":"Bouzas EA, Scott MH, Mastorakos G, Chrousos GP, Kaiser-Kupfer MI (1960) Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 1993(111):1229\u20131233","journal-title":"Arch. Ophthalmol."},{"key":"785_CR10","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/S0161-6420(02)01117-X","volume":"109","author":"CA Carvalho-Recchia","year":"2002","unstructured":"Carvalho-Recchia CA, Yannuzzi LA, Negr\u00e3o S, Spaide RF, Freund KB, Rodriguez-Coleman H, Lenharo M, Iida T (2002) Corticosteroids and central serous chorioretinopathy. Ophthalmology 109:1834\u20131837","journal-title":"Ophthalmology"},{"key":"785_CR11","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/cphy.c130044","volume":"4","author":"E Gomez-Sanchez","year":"2014","unstructured":"Gomez-Sanchez E, Gomez-Sanchez CE (2014) The multifaceted mineralocorticoid receptor. Compr Physiol 4:965\u2013994","journal-title":"Compr Physiol"},{"key":"785_CR12","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1046\/j.1523-1755.2000.00976.x","volume":"57","author":"N Farman","year":"2000","unstructured":"Farman N, Bocchi B (2000) Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int 57:1364\u20131369","journal-title":"Kidney Int"},{"key":"785_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000345243","volume":"50","author":"M Briet","year":"2013","unstructured":"Briet M, Schiffrin EL (2013) Vascular actions of aldosterone. J\u00a0Vasc Res 50:89\u201399","journal-title":"J Vasc Res"},{"key":"785_CR14","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-14-0471","volume":"224","author":"MJ Young","year":"2015","unstructured":"Young MJ, Rickard AJ (2015) Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals. J\u00a0Endocrinol 224:R1\u2013R13","journal-title":"J Endocrinol"},{"key":"785_CR15","first-page":"221","volume":"8","author":"N Golestaneh","year":"2002","unstructured":"Golestaneh N, Picaud S, Mirshahi M (2002) The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity. Mol Vis 8:221\u2013225","journal-title":"Mol Vis"},{"key":"785_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCRESAHA.108.176008","volume":"104","author":"JL Wilkinson-Berka","year":"2009","unstructured":"Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG (2009) Identification of a\u00a0retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res 104:124\u2013133","journal-title":"Circ Res"},{"key":"785_CR17","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1096\/fj.09-154344","volume":"24","author":"M Zhao","year":"2010","unstructured":"Zhao M, Valamanesh F, Celerier I, Savoldelli M, Jonet L, Jeanny J\u2011C, Jaisser F, Farman N, Behar-Cohen F (2010) The neuroretina is a\u00a0novel mineralocorticoid target: aldosterone up-regulates ion and water channels in M\u00fcller glial cells. FASEB J 24:3405\u20133415","journal-title":"FASEB J."},{"key":"785_CR18","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI61427","volume":"122","author":"M Zhao","year":"2012","unstructured":"Zhao M, C\u00e9l\u00e9rier I, Bousquet E, Jeanny J\u2011C, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F (2012) Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J\u00a0Clin Invest 122:2672\u20132679","journal-title":"J Clin Invest"},{"key":"785_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-016-0377-2","author":"F Pichi","year":"2016","unstructured":"Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci P, Central Serous Chorioretinopathy Study Group. (2016) Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol. \n                    https:\/\/doi.org\/10.1007\/s10792-016-0377-2","journal-title":"Int Ophthalmol"},{"key":"785_CR20","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1126\/science.126.3281.1015","volume":"126","author":"CM Kagawa","year":"1957","unstructured":"Kagawa CM, Cella JA, Van Arman CG (1957) Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science 126:1015\u20131016","journal-title":"Science"},{"key":"785_CR21","doi-asserted-by":"publisher","first-page":"3A","DOI":"10.1016\/0002-9149(93)90238-8","volume":"71","author":"KT Weber","year":"1993","unstructured":"Weber KT, Villarreal D (1993) Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 71:3A\u201311A","journal-title":"Am J Cardiol"},{"key":"785_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","volume":"29","author":"P Gardiner","year":"1989","unstructured":"Gardiner P, Schrode K, Quinlan D, Martin BK, Boreham DR, Rogers MS, Stubbs K, Smith M, Karim A (1989) Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J\u00a0Clin Pharmacol 29:342\u2013347","journal-title":"J Clin Pharmacol"},{"key":"785_CR23","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a\u00a0selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N\u00a0Engl J Med 348:1309\u20131321","journal-title":"N Engl J Med"},{"key":"785_CR24","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","volume":"31","author":"CS Cook","year":"2003","unstructured":"Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW (2003) Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos 31:1448\u20131455","journal-title":"Drug. Metab. Dispos."},{"key":"785_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","volume":"10","author":"DA Sica","year":"2005","unstructured":"Sica DA (2005) Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10:23\u201329","journal-title":"Heart Fail Rev"},{"key":"785_CR26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N\u00a0Engl J Med 341:709\u2013717","journal-title":"N Engl J Med"},{"key":"785_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311096","author":"X Sun","year":"2017","unstructured":"Sun X, Shuai Y, Fang W, Li J, Ge W, Yuan S, Liu Q (2017) Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Br J Ophthalmol. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311096","journal-title":"Br J Ophthalmol"},{"key":"785_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13491","author":"R Schwartz","year":"2017","unstructured":"Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, Shulman S, Guzner-Gur H, Loewenstein A, Goldstein M (2017) Eplerenone for chronic central serous chorioretinopathy\u2014a randomized controlled prospective study. Acta Ophthalmol (Copenh). \n                    https:\/\/doi.org\/10.1111\/aos.13491","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"785_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/iae.0000000000001649","author":"E Rahimy","year":"2017","unstructured":"Rahimy E, Pitcher JD, Hsu J, Adam MK, Shahlaee A, Samara WA, Vander JF, Kaiser RS, Chiang A, Spirn MJ, Fineman MS (2017) A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior). Retina. \n                    https:\/\/doi.org\/10.1097\/iae.0000000000001649","journal-title":"Retina"},{"key":"785_CR30","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","volume":"35","author":"E Bousquet","year":"2015","unstructured":"Bousquet E, Beydoun T, Rothschild P\u2011R, Bergin C, Zhao M, Batista R, Brandely M\u2011L, Couraud B, Farman N, Gaudric A, Chast F, Behar-Cohen F (2015) Spironolactone for nonresolving central serous chorioretinopathy. Retina 35:2505\u20132515","journal-title":"Retina"},{"issue":"3","key":"785_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4103\/jovr.jovr_139_16","volume":"12","author":"KG Falavarjani","year":"2017","unstructured":"Falavarjani KG, Amirsardari A, Habibi A, Eshaghi A, Bakhti S, Aghdam KA (2017) Visual and Anatomical Outcomes of Spironolactone Therapy in Patients with Chronic Central Serous Chorioretinopathy. J Ophthalmic Vis Res 12(3):281\u2013289. \n                    https:\/\/doi.org\/10.4103\/jovr.jovr_139_16","journal-title":"J Ophthalmic Vis Res"},{"key":"785_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00417-016-3436-5","volume":"255","author":"TR Herold","year":"2017","unstructured":"Herold TR, Rist K, Priglinger SG, Ulbig MW, Wolf A (2017) Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR). Graefes Arch Clin Exp Ophthalmol 255:221\u2013229","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"6","key":"785_CR33","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/IAE.0000000000001303","volume":"37","author":"R Gergely","year":"2017","unstructured":"Gergely R, Kov\u00e1cs I, Schneider M, Resch M, Papp A, R\u00e9cs\u00e1n Z, Nagy ZZ, Ecsedy M (2017) Antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina 37(6):1084\u20131091. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000001303","journal-title":"Retina"},{"issue":"12","key":"785_CR34","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00417-014-2780-6","volume":"252","author":"TR Herold","year":"2014","unstructured":"Herold TR, Prause K, Wolf A, Mayer WJ, Ulbig MW (2014) Spironolactone in the treatment of central serous chorioretinopathy\u00a0\u2013 a case series. Graefes Arch Clin Exp Ophthalmol 252(12):1985\u20131991. \n                    https:\/\/doi.org\/10.1007\/s00417-014-2780-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"785_CR35","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1097\/IAE.0b013e318297a07a","volume":"33","author":"E Bousquet","year":"2013","unstructured":"Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F (2013) Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.\nRetina 33(10):2096\u20132102. \n                    https:\/\/doi.org\/10.1097\/IAE.0b013e318297a07a","journal-title":"Retina"},{"key":"785_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001913","author":"JH Lee","year":"2017","unstructured":"Lee JH, Lee SC, Kim H, Lee CS (2017) Comparison of short-term efficacy between oral spironolactone treatment and photodynamic therapy for the treatment of nonresolving central serous chorioretinopathy. Retina. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000001913","journal-title":"Retina"},{"issue":"11","key":"785_CR37","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00417-016-3373-3","volume":"254","author":"B Cakir","year":"2016","unstructured":"Cakir B, Fischer F, Ehlken C, B\u00fchler A, Stahl A, Schlunck G, B\u00f6hringer D, Agostini H, Lange C (2016) Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 254(11):2151\u20132157","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"785_CR38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.5301\/ejo.5000727","volume":"26","author":"C Leisser","year":"2016","unstructured":"Leisser C, Hirnschall N, Hackl C, Plasenzotti P, Findl O (2016) Eplerenone in patients with chronic recurring central serous chorioretinopathy. Eur J Ophthalmol 26(5):479\u2013484. \n                    https:\/\/doi.org\/10.5301\/ejo.5000727","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"785_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000444058","volume":"56","author":"KG Kapoor","year":"2016","unstructured":"Kapoor KG, Wagner AL (2016) Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis. Ophthalmic Res 56(1):17\u201322. \n                    https:\/\/doi.org\/10.1159\/000444058","journal-title":"Ophthalmic Res"},{"issue":"2","key":"785_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/tvst.5.2.2","volume":"5","author":"A Daruich","year":"2016","unstructured":"Daruich A, Matet A, Dirani A, Gallice M, Nicholson L, Sivaprasad S, Behar-Cohen F (2016) Mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl Vis Sci Technol 5(2):2","journal-title":"Transl Vis Sci Technol"},{"issue":"3","key":"785_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/IAE.0000000000000748","volume":"36","author":"Q Ghadiali","year":"2016","unstructured":"Ghadiali Q, Jung JJ, Yu S, Patel SN, Yannuzzi LA (2016) Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study. Retina 36(3):611\u2013618. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000000748","journal-title":"Retina"},{"key":"785_CR42","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2147\/OPTH.S86778","volume":"9","author":"EK Chin","year":"2015","unstructured":"Chin EK, Almeida DRP, Roybal CN, Niles PI, Gehrs KM, Sohn EH, Boldt HC, Russell SR, Folk JC (2015) Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy. Clin Ophthalmol 9:1449\u20131456. \n                    https:\/\/doi.org\/10.2147\/OPTH.S86778","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"785_CR43","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3928\/23258160-20150422-06","volume":"46","author":"DA Salz","year":"2015","unstructured":"Salz DA, Pitcher JD 3rd, Hsu J, Regillo CD, Fineman MS, Elliott KS, Vander JF, Fischer DH, Spirn MJ (2015) Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg Lasers Imaging Retina 46(4):439\u2013444. \n                    https:\/\/doi.org\/10.3928\/23258160-20150422-06","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"2","key":"785_CR44","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3980\/j.issn.2222-3959.2015.02.17","volume":"8","author":"RP Singh","year":"2015","unstructured":"Singh RP, Sears JE, Bedi R, Schachat AP, Ehlers JP, Kaiser PK (2015) Oral eplerenone for the management of chronic central serous chorioretinopathy. Int J Ophthalmol 8(2):310\u2013314. \n                    https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2015.02.17","journal-title":"Int J Ophthalmol"},{"key":"785_CR45","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/bjo.72.11.829","volume":"72","author":"L Ficker","year":"1988","unstructured":"Ficker L, Vafidis G, While A, Leaver P (1988) Long-term follow-up of a\u00a0prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 72:829\u2013834","journal-title":"Br J Ophthalmol"},{"key":"785_CR46","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/bjo.68.11.815","volume":"68","author":"CM Gilbert","year":"1984","unstructured":"Gilbert CM, Owens SL, Smith PD, Fine SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68:815\u2013820","journal-title":"Br J Ophthalmol"},{"key":"785_CR47","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ophtha.2013.11.040","volume":"121","author":"JI Lim","year":"2014","unstructured":"Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF, Macula Society CSC Collaborative Study Group, Research and Education Committee and Website Committee (2014) Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 121:1073\u20131078","journal-title":"Ophthalmology"},{"key":"785_CR48","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ajo.2009.08.026","volume":"149","author":"M Reibaldi","year":"2010","unstructured":"Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F, Cannemi V, Zagari M, Boscia F (2010) Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a\u00a0nonrandomized clinical trial. Am J Ophthalmol 149:307\u2013315.e2","journal-title":"Am J Ophthalmol"},{"key":"785_CR49","doi-asserted-by":"publisher","unstructured":"Berufsverband der Augen\u00e4rzte Deutschlands e.\u2009V. (BVA); Deutsche Ophthalmologische Gesellschaft (DOG); Retinologische Gesellschaft e.\u2009V. (RG) (2018) Stellungnahme von DOG, RG und BVA zur Chorioretinopathia centralis serosa (CCS) Ophthalmologe 115(5):388\u2013399. \n                    https:\/\/doi.org\/10.1007\/s00347-018-0680-6","DOI":"10.1007\/s00347-018-0680-6"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-018-0785-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-018-0785-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-018-0785-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T07:38:46Z","timestamp":1569397126000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-018-0785-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1007\/s00347-018-0785-y","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,25]]},"assertion":[{"value":"25 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Cakir, H.\u00a0Agostini und C.\u00a0Lange geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}